Table 1.
Clinical Characteristics of All Subjects, and the STEMI and NSTEMI-UAP Groups
| All subjects (n=924) |
STEMI (n=534) |
NSTEMI-UAP (n=390) |
P valueA | |
|---|---|---|---|---|
| Age (years) | 65.9±12.0 | 64.6±12.6 | 67.7±10.9 | <0.01 |
| Male sex | 738 (80) | 429 (80) | 309 (79) | 0.67 |
| Hypertension | 508 (55) | 264 (50) | 244 (63) | <0.01 |
| Diabetes | 246 (27) | 111 (21) | 135 (35) | <0.01 |
| Dyslipidemia | 620 (67) | 339 (64) | 281 (72) | <0.01 |
| Current smoker | 189 (21) | 130 (25) | 59 (15) | <0.01 |
| Family history of IHD | 86 (10) | 50 (10) | 36 (10) | 0.98 |
| Ejection fraction (%) | 54.9±9.9 | 51.8±10.0 | 57.1±9.6 | <0.01 |
| Laboratory data | ||||
| Hemoglobin (g/dL) | 13.2±1.8 | 13.5±1.8 | 12.9±1.7 | <0.01 |
| Creatinine (mg/dL) | 1.0±1.0 | 0.96±0.78 | 1.08±1.2 | 0.55 |
| Total cholesterol (mg/dL) | 171±44 | 174±46 | 168±42 | 0.13 |
| Triglyceride (mg/dL) | 136±76 | 136±75 | 134±77 | 0.65 |
| HDL-C (mg/dL) | 43±13 | 42±12 | 43±13 | 0.38 |
| LDL-C (mg/dL) | 102±37 | 103±38 | 102±37 | 0.97 |
| FBS (mg/dL) | 137±58 | 142±62 | 127±50 | 0.02 |
| HbA1c (%) | 6.3±1.0 | 6.2±1.0 | 6.4±1.0 | 0.02 |
| BNP (pg/mL) | 110 [46–239] | 124 [53–245] | 95 [35–201] | 0.06 |
| NT-proBNP (pg/mL) | 494 [157–1,084] | 588 [248–1,345] | 364 [130–926] | <0.01 |
| CRP (mg/dL) | 1.12±2.52 | 1.13±2.81 | 1.11±1.96 | <0.01 |
| hsCRP (mg/dL) | 0.83±1.57 | 0.74±1.42 | 0.90±1.67 | 0.46 |
| Medications | ||||
| ASA | 889 (96) | 518 (97) | 371 (95) | 0.14 |
| DAPT | 651 (75) | 458 (86) | 233 (60) | <0.01 |
| ACEI | 545 (59) | 425 (80) | 120 (31) | <0.01 |
| ARB | 178 (19) | 61 (11) | 117 (30) | <0.01 |
| β-blockers | 720 (78) | 447 (84) | 273 (70) | <0.01 |
| CCB | 219 (24) | 80 (15) | 139 (36) | <0.01 |
| Statin | 851 (92) | 503 (94) | 348 (89) | <0.01 |
| OADs | 237 (26) | 108 (20) | 129 (33) | <0.01 |
| Insulin | 37 (4) | 13 (2) | 24 (6) | <0.01 |
Data are presented as the mean±SD, median [interquartile range], or as n (%). AP values are for comparisons of the STEMI vs. NSTEMI-UAP groups. ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, aspirin; BNP, B-type natriuretic peptide; CCB, calcium channel blockers; DAPT, dual antiplatelet therapy; FBS, fasting blood sugar; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IHD, ischemic heart disease; LDL-C, low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro B-type natriuretic peptide; NSTEMI-UAP, non-STEMI plus unstable angina pectoris; OADs, oral antidiabetic drugs; STEMI, ST-elevation myocardial infarction.